Medtronic plc has announced that BrainSense Adaptive Deep Brain Stimulation (aDBS) what it says is the world’s first closed-loop DBS system for people with Parkinson’s – has been recognised by TIME on its annual list of Best Inventions.
There are over 10 million people living with Parkinson’s disease globally, according to the Global Burden of Disease Study 2021, and while there is currently no cure. Medtronic deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years.
Medtronic recently enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for people with Parkinson’s. This feature personalises therapy based on a patient’s brain activity in real time – minimising the need for patients to manually adjust stimulation.
Medtronic spent more than twenty years developing a complete, sensing-enabled DBS system leveraging exclusive BrainSense technology to detect, capture, and classify different brain signals. Medtronic says this advancement puts the company at the forefront of incorporating therapeutic brain-computer interface (BCI) technology into DBS therapy and BrainSense Adaptive DBS presents the largest commercial launch of BCI technology – ever.
“Medtronic BrainSense Adaptive Deep Brain Stimulation marks a new era in neuromodulation and the use of therapeutic brain-computer interface technology to restore human health. We congratulate Medtronic on joining this year’s esteemed list of Best Inventions.” — TIME Editors, Best Inventions 2025
Medtronic received both CE Mark and U.S. FDA approval for BrainSense aDBS earlier this year and already more than 1,000 patients worldwide have received the adaptive therapy. Recently, the pivotal ADAPT-PD study was published in the Journal of the American Medical Association (JAMA) Neurology showing clinical effectiveness, long-term safety, and patient preference for Medtronic BrainSense aDBS.
“We’re honoured that our BrainSense Adaptive DBS technology for people with Parkinson’s is being recognsed as one of the year’s most important medical innovations,” said Paolo Di Vincenzo, president of the Neuromodulation business, which is part of the Neuroscience portfolio at Medtronic. “This groundbreaking technology represents intentional innovation that responds to a patient’s changing needs, equips clinicians with unparalleled insights, and sets a new standard for DBS therapy.”
Related
The post Medtronic BrainSense Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions first appeared on TechToday.
This post originally appeared on TechToday.